HTC
ANIP icon

Haverford Trust Company’s ANI Pharmaceuticals ANIP Stock Holding History

Haverford Trust Company’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,942
Closed -$864K – 420
2025
Q4 		$864K Buy
+10,942
New +$947K 0.01% 239
2018
Q3 		– Sell
-12,240
Closed -$818K – 300
2018
Q2 		$818K Buy
+12,240
New +$764K 0.02% 173

Other funds holding ANIP

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.72B AUM 1.39% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Haverford Trust Company's ANIP Position: Q1 2026 in Review

Haverford Trust Company sold out of ANI Pharmaceuticals (ANIP) in Q1 2026, closing a stake of 10,942 shares — an estimated $864K sold.

Haverford Trust Company first reported a position in ANIP in Q2 2018 and held it in 2 quarters. The position peaked at $864K in Q4 2025. 281 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Haverford Trust Company reported no remaining ANI Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Haverford Trust Company sold 10,942 ANI Pharmaceuticals shares in Q1 2026, an estimated $864K.
  • Haverford Trust Company first reported a position in ANI Pharmaceuticals in Q2 2018 and held it in 2 quarters.
  • Haverford Trust Company's ANI Pharmaceuticals position peaked at $864K in Q4 2025.
  • 281 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Haverford Trust Company's 13F filing for Q1 2026, filed 11 May 2026.